HealthEquity reports record revenue; raises FY2027 guidance after strong Q4

HEALTHEQUITY, INC.

2026-FY EPS reported $2.46 revenue$1,313,429,000

FY2026 revenue $1.31B (+9% YoY); net income $215.2M (+123% YoY); EPS $2.46.
Q4 revenue $334.6M (+7% YoY); adjusted EBITDA $132.9M (+23%); margin 40%.
Total HSA assets $36.5B (+14%); added 1M new HSAs from sales for second straight year.
Raised FY2027 guidance: revenue $1.405-$1.415B; adjusted EBITDA $618-$628M.
Returned $301.7M to shareholders via stock repurchases in FY2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

HEALTHEQUITY, INC. reported the fourth quarter ended January 31, 2026 results: revenue $334.6 million, net income $49.7 million, EPS $0.58 per diluted share. Guidance raised.

Period: the fourth quarter ended January 31, 2026
Revenue: $334.6 million
Net income: $49.7 million
EPS: $0.58 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

Revenue for the fourth quarter ended January 31, 2026 was $334.6 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

HEALTHEQUITY, INC. reported the fiscal year ended January 31, 2026 results: revenue $1.31 billion, net income $215.2 million, EPS $2.46 per diluted share. Guidance raised.

Period: the fiscal year ended January 31, 2026
Revenue: $1.31 billion
Net income: $215.2 million
EPS: $2.46 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

Revenue for the fiscal year ended January 31, 2026 was $1.31 billion

View on SEC.gov

Browse all earnings releases →

HEALTHEQUITY, INC. filing history →

Source: SEC EDGAR

accession 0001428336-26-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.